Avadel Pharmaceuticals (AVDL) Gains from Investment Securities: 2009-2022
Historic Gains from Investment Securities for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Dec 2022 value amounting to -$29.1 million.
- Avadel Pharmaceuticals' Gains from Investment Securities rose 40712.50% to $3.3 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$29.1 million, marking a year-over-year decrease of 17922.09%. This contributed to the annual value of -$29.1 million for FY2022, which is 38334.21% down from last year.
- According to the latest figures from FY2022, Avadel Pharmaceuticals' Gains from Investment Securities is -$29.1 million, which was down 38,334.21% from $76,000 recorded in FY2021.
- In the past 5 years, Avadel Pharmaceuticals' Gains from Investment Securities registered a high of $776,000 during FY2018, and its lowest value of -$29.1 million during FY2022.
- Over the past 3 years, Avadel Pharmaceuticals' median Gains from Investment Securities value was -$1.7 million (recorded in 2020), while the average stood at -$10.2 million.
- In the last 5 years, Avadel Pharmaceuticals' Gains from Investment Securities soared by 208.68% in 2018 and then tumbled by 38,334.21% in 2022.
- Yearly analysis of 5 years shows Avadel Pharmaceuticals' Gains from Investment Securities stood at $776,000 in 2018, then plummeted by 81.96% to $140,000 in 2019, then slumped by 1,315.00% to -$1.7 million in 2020, then soared by 104.47% to $76,000 in 2021, then crashed by 38,334.21% to -$29.1 million in 2022.